On Thursday, the Trump administration asked the Supreme Court to grant them a stay on the Massachusetts vs Kennedy/ APHA vs NIH ruling. This decision will occur on the shadow docket, with no formal hearing.
I have certainly lost a lot of hope in this process, but it is nice to see some people are still advocating for us. Thanks @jeremymberg.bsky.social
👇👇👇👇
I am one of these faces.
I certainly do feel like my life has been turned upside down multiple times this year, but I will always love my #NIHMOSAIC family and I am so glad we have people like @jeremymberg.bsky.social fighting for us ❤️
Sometimes you don’t realize the full burden you’ve been carrying –of being implicitly treated as a second-class citizen whose life isn’t worth preserving, of people working to fix health inequalities in this country being persecuted, of the crushing *silence* around it – until someone calls it out.
The NIH can’t award ANY grants to outside researchers under new WH restriction, reports @wsj.com.
The pause came in the form of a footnote from OMB Director Vought, in a document that doles out federal funds to the NIH.
Prelude to rescissions, especially after his comments over the weekend?
Public comment on this new "no animal only studies" is open here:
www.fda.gov/news-events/...
It closes next Monday.
Video
The full ruling explaining why NIH grant cuts are illegal came out today.
It's just as blistering as the judge's oral remarks. And it uncovers fresh details in DOGE's role orchestrating the cuts — and on the cuts at Columbia.
Here are my top highlights from the 103-page ruling. 🧵
An NIH staffer reacts to today's ruling:
"I'm looking forward to the day that we are so slammed with work trying to reinstate everything that we had to terminate illegally — I'll work 24/7 to make that happen if I can."
The National Institutes of Health can’t award grants to outside researchers under a new White House restriction.
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
www.drugdiscoverytrends.com
Jay Bhattacharya seemed genuinely surprised to learn that diversity applicants compete in the same payline with applicants to standard opportunities. So terminating these grants (when they outperformed their peers) is blatant discrimination.
Yet, we would not commit to correcting this
